Fms-like tyrosine kinase 3 ligand - Celldex Therapeutics

Drug Profile

Fms-like tyrosine kinase 3 ligand - Celldex Therapeutics

Alternative Names: CDX-301; Flt-3 ligand; Flt3-L; Mobista; rhuFlt3L

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; Celldex Therapeutics Inc; Icahn School of Medicine at Mount Sinai; National Cancer Institute (USA)
  • Class Adjuvants; Antineoplastics; Cytokines; Recombinant proteins
  • Mechanism of Action Dendritic cell stimulants; Fms-like tyrosine kinase 3 stimulants; Haematopoiesis stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II B cell lymphoma
  • Discontinued Autoimmune disorders; Infections; Non-Hodgkin's lymphoma; Solid tumours; Stem cell mobilisation

Most Recent Events

  • 03 Dec 2016 Preclinical data presented at the 58th Annual Meeting and Exposition of the American Society of Haematology
  • 08 Aug 2016 Fms-like tyrosine kinase 3 ligand is still in phase-I/II trials for B-cell lymphoma (Combination therapy, Low-grade disease) in USA (Intratumoural) (NCT01976585),
  • 05 May 2016 Discontinued - Phase-II for Stem cell mobilisation in USA (Parenteral) because Celldex is prioritising its resourses
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top